Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$6.66
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.66
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$3.45 - $15.40
Previous CloseN/A
Volume477.34K
Average Volume (3M)3.86M
Market Cap
$1.88B
Enterprise Value$684.09M
Total Cash (Recent Filing)$466.01M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Jul 30, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume4,610,018
30 Day Avg. Volume3,859,633
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.87
Forecast
1Y Price Target
$24.43Price Target Upside266.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$2.31M
Bulls Say, Bears Say
Bulls Say
Phase III Durability & EfficacyTwo large, well-controlled pivotal trials (005 and 006) with ~1,000+ patients and blinded 26-week follow-up demonstrate reproducible rapid onset and durable benefit. Durable efficacy in a severe, chronic TRD cohort strengthens the clinical value proposition, improves regulatory credibility and underpins longer-term payer conversations and adoption assumptions.
Rolling NDA & Priority VoucherAlignment on a rolling NDA and receipt of a Commissioner’s National Priority Voucher materially shorten potential FDA review timing after final submission. This structural regulatory advantage reduces time-to-market risk versus peers, enabling faster commercialization planning and earlier revenue opportunity if remaining datasets and sequencing proceed as expected.
Cash Runway & Commercial ReadinessQ1 financing and warrant exercises provided a runway into 2028, allowing sustained investment in launch infrastructure, site engagement and payer work. Combined with rapid commercial hiring and experienced executives, this reduces near-term refinancing risk and supports durable build-out of field capabilities needed for a complex, clinic-delivered therapy.
Bears Say
Pre-revenue & Persistent Cash BurnThe company remains pre-revenue with large, recurring operating losses and deeply negative operating/free cash flow. Persistent cash burn implies ongoing dependence on external financing until commercial revenues materialize, which can dilute shareholders and constrain strategic flexibility over the medium term if reimbursement and launch timelines slip.
Regulatory Sequencing UncertaintyKey regulatory elements remain contingent: whether an advisory committee is convened, the timing of the final NDA submission, and DEA rescheduling sequencing. Even with a priority voucher, uncertain sequencing between FDA review, REMS development and DEA action can delay patient access and revenue realization, affecting multi-quarter commercialization plans.
Reimbursement Path Still Immature (CPT Category III)Current CPT codes are tracking (Category III) and lack established RVU valuation. Moving to Category I and securing durable RVUs requires committee timelines, real-world data and RUC processes. This structural reimbursement uncertainty can constrain revenue per treatment and slow payer coverage decisions, impacting long-term access and unit economics.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $3.45 and its highest was $15.40 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $1.88B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Jul 30, 2026 which is in 20 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of -$0.439 by $1.149.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.39.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of $0.71 in its last earnings report, beating expectations of -$0.439. Following the earnings report the stock price went up 16.969%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.43 (266.80% Upside)
$24.43 (266.80% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
303.61%
12-Months-Change
Fundamentals
Return on Equity
-151.02%
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$24.43
▲(266.80% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.41% Insiders
1.29% Mutual Funds
0.39% Other Institutional Investors
93.77% Public Companies and Individual Investors